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Optimization of methods for ruling out Bacillus
anthracis leads to increased yields, faster turnaround
times, and a lighter workload. We used 72 environmental
non–B. anthracis bacilli to validate methods for ruling out
B. anthracis. Most effective were the use of horse blood
agar, motility testing after isolates had a 2-h incubation in
trypticase soy broth, and screening isolates with a B.
anthracis–selective agar.
T
he potential use of Bacillus anthracis as a bioterrorism
agent has long been suspected. In 2001, biologic war-
fare became a reality (1), and microbiology laboratories
around the world faced the problem of establishing rapid
protocols for ruling out the presence of B. anthracis in
clinical or environmental samples. To identify B.
anthracis, both conventional and molecular methods have
been applied. Presumptive identification is based on
demonstrating a lack of β-hemolysis on sheep (2,3) or
horse (3) blood agar plates and the organism’s lack of
motility (2,3). B. anthracis–specific polymerase chain
reaction (PCR) assays may also be applied for faster pre-
liminary characterization of isolates. Several protocols tar-
geting chromosomal, pXO1, or pXO2 plasmid sequences
have been described (4–9).
Since September 2001, many incidents of alleged
bioterrorism have occurred in Greece, as in other coun-
tries. Most samples from these incidents are being exam-
ined at our Department of Microbiology, National and
Kapodistrian University of Athens Medical School. We
isolated many bacilli, none of them B. anthracis, but
encountered difficulties regarding the methods of ruling
out B. anthracis. We realized that bacilli might produce
different hemolysis patterns on blood agar plates made of
blood from different species, and that the utility of the B.
anthracis-selective agar, PLET (polymyxin, lysozyme,
EDTA, thallous acetate) (10), was unknown for this type of
isolates. We detected occasional false-positive results with
PCR protocols previously evaluated by using reference
strains rather than field isolates and tried to improve sensi-
tivity of motility detection methods.
Few investigations have dealt with laboratory aspects
of the recent bioterrorism attack (9,11,12), and a detailed
evaluation of the methods for ruling out B. anthracis has
not been reported. We used 72 environmental non–B.
anthracis bacilli to validate and optimize methods for rul-
ing out B. anthracis. We compared blood agar plates made
of sheep, horse, and human blood for their ability to
demonstrate  β-hemolysis and three simple methods for
motility detection. We also evaluated the specificity of
PLET agar and four previously described PCR assays.
The Study
During a 12-month period (10/2001–9/2002), 199 con-
secutive environmental specimens were submitted for pos-
sible detection of B. anthracis. Seventy-two Bacillus spp.
strains were isolated; none was B. anthracis. Strains were
stored at –70° C and retrospectively analyzed.
Hemolysis types were determined by subculturing them
on 5% horse, sheep, and human blood agar plates: α-, β-,
and γ-hemolysis were defined, according to standard crite-
ria (13). Strong β-hemolysis was characterized as hemoly-
sis clearly extending the colony margin, and weak
β-hemolysis was characterized by a narrower hemolysis
zone or slight hemolysis below colonies. Strains were
additionally plated on PLET agar (10). Cultures were incu-
bated at 35°C for 18–24 h in air; blood agar plates were
incubated for 48 h. Motility testing was performed by
using sterile H2O at time 0, as well as trypticase soy broth
(TSB) at time 0 and after a 2-h incubation at 35°C. Part of
a colony was dissolved in H2O and TSB and examined
microscopically (2). Media were supplied from Bioprepare
(Gerakas, Greece), except for human blood agar plates pre-
pared in house with red blood cell units obtained from
blood banks and a blood agar base (Scharlau Chemie,
Barcelona, Spain).
Isolates were tested by three B. anthracis–specific PCR
protocols amplifying a 152-, a 747-, and a 264-bp fragment
of the chromosomal Ba813, the pagA (pXO1), and the
capC gene (pXO2) sequences, respectively (5). APCR rec-
ommended by the World Health Organization, which tar-
gets a 639-bp sequence of the chromosomal B. anthracis
S-layer gene, was also performed (8). Crude DNA was
extracted by boiling colonies in H2O. Control strains
included the NC08234-03 B. anthracis Sterne strain
(pXO1+/pXO2–), a B. anthracis strain isolated from the
malignant pustule of an agricultural anthrax patient, and
the Bacillus subtilis EO-1 reference strain (kindly provid-
ed by the Hellenic Agricultural Ministry). Two microbiol-
ogists independently assessed all results. The Fisher exact
test was performed for the statistical analysis.
Diverse hemolytic activity was demonstrated by the 72
bacilli on different blood agar plates. At 24 h, strong β-
hemolysis was produced by 55 (76%), 41 (57%), and 55
(76%) strains on human, sheep, and horse blood agar
plates, respectively, while 6 (8%), 10 (14%) and 7 (10%)
DISPATCHES
732 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 4, April 2004
*National and Kapodistrian University of Athens Medical School,
Athens, Greece; and †Ministry of Health, Athens, Greece strains demonstrated weak β-hemolysis (Table).
Prolongation of incubation to 48 h resulted in increased
detection of strong β-hemolysis on all media. 
Both B. anthracis strains produced γ-hemolysis on all
media at 24 h, except for slight β-hemolysis below areas of
confluent growth on human blood agar plates. After 48 h
they remained γ-hemolytic on horse and sheep blood agar
plates; however, both produced strong β-hemolysis on
human blood agar plates.
At time zero of incubation, motility was detected in 33
(46%) and 45 strains (63%) examined in H2O and TSB,
respectively. All isolates motile in H2O were also motile in
TSB. The 2-h incubation step in TSB detected another 13
motile strains (total number of motile strains, 58; 81%) and
made recognition of motility much easier.
The capC and pagA gene sequences were not ampli-
fied; however, the Ba813 sequence was amplified in seven
strains (10%; specificity 90%), and the S-layer sequence
was amplified in another two strains (3%; specificity
97%). Twenty-four isolates (33%) grew on PLET; 21 of
them were uniformly β-hemolytic. A positive correlation
between the ability to grow on PLET and BA813 PCR-
positivity was detected. Five out of 24 strains (21%) that
grew on PLET were positive by this PCR in comparison
with 2 of 48 strains (4%) that did not grow on PLET
(Fisher exact test, p = 0.037). 
Conclusions
Although other genera are known to produce distinct
hemolysis types on different blood agar plates (14), com-
parative studies for bacilli have not been reported. Most
environmental bacilli in our study were β-hemolytic.
However, various blood agar plates manifested different
abilities to support the expression of β-hemolysis as well
as to demonstrate weak and strong β-hemolysis. In that
respect, it is important to underline that weak β-hemolysis
is interpreted with caution; isolates will be incubated for
another 24 h or considered nonhemolytic strains. β-hemol-
ysis was easier to recognize on all media after 48 h, but
sheep blood agar plates were the least effective medium in
detecting  β-hemolysis. Finally, β-hemolysis results
obtained with horse and human blood agar plates, although
not identical, were usually in agreement and differed from
those obtained with sheep blood agar plates (data not
shown).
The production of strong β-hemolysis on human blood
agar plates by the B. anthracis strains was unexpected, as
this organism has been considered traditionally non-
hemolytic. Recently, however, the ability of B. anthracis to
express β-hemolysis was reported (15,16). Broth culture
supernatants possessed hemolytic activity against human
and sheep erythrocytes, whereas richness of media affect-
ed hemolysis expression (15). Another study demonstrated
the induction of strong β-hemolysis on human but not
sheep blood agar plates under anaerobic conditions (16). In
fact, a study conducted in 1957 reported 45 β-hemolytic
strains among 120 B. anthracis isolates that had been cul-
tured on rabbit blood agar plates (17). Therefore, withhold-
ing the use of human blood agar plates would be prudent;
horse blood agar plates should be used as the most
“informative” medium. 
According to our findings, the 2-h incubation of bacilli
in TSB greatly improves recognition of motile strains.
Increased motility detection using TSB rather than H2O
has been demonstrated with 12 non–B. anthracis strains
(18), though test performance after incubation was not
assessed. Apparently, motile bacilli become immobilized
in distilled water, while the practice of incubating them in
a rich broth until they reach exponential growth phase was
actually recommended in the past (19).
All bacilli tested negative for the presence of capC and
pagA sequences, but seven strains were positive for Ba813.
All were strongly β-hemolytic and five were motile. These
results prompted us to assess the specificity of the S-layer
PCR, which, to our knowledge, has not been evaluated
before. Only two strains, different from the above seven,
were positive: a motile, strongly β-hemolytic strain and a
nonmotile, γ-hemolytic strain.
With the exception of the Laboratory Response
Network real-time PCR (9), the specificity of other PCR
protocols (4–8,20) has not been evaluated before by testing
field isolates from suspected bioterrorism incidences.
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Table. Numbers (%) of environmental Bacillus spp. isolates exhibiting various types of hemolysis on human, sheep, and horse blood 
agar plates at 24 and 48 hours of incubation 
  Incubation time 
  24 h  48 h 
Human
a  Sheep
a  Horse
a  Human  Sheep  Horse 
Type of hemolysis  No  (%)  No  (%)  No  (%)  No  (%)  No  (%)  No  (%) 
α  1  (1.4)  5  (6.9)  0  (0)  0  (0)  0  (0)  1  (1.4) 
γ  10  (13.9)  16  (22.3)  10  (13.9)  4  (5.6)  9  (12.5)  2  (2.8) 
Total β  61  (84.7)  51  (70.8)  62  (86.1)  68  (94.4)  63  (87.5)  69  (95.8) 
Strong β  55  (76.4)  41  (56.9)  55  (76.4)  65  (90.3)  55  (76.4)  66  (91.6) 
Weak β  6  (8.3)  10  (13.9)  7  (9.7)  3  (4.1)  8  (11.1)  3  (4.2) 
Total  72    72    72    72    72    72   
aHuman, sheep, and horse refer to the respective blood agars. False-positive results have been reported with other cap
sequence PCR assays (4,6), while efforts to establish a spe-
cific chromosomal assay have been frustrating (6,7,20). As
B. anthracis strains cured from one or both plasmids exist
naturally or may be obtained in vitro (3), and false-nega-
tive results may be encountered with plasmid-specific
PCR assays (4), the availability of a chromosomal PCR is
desirable. Our results indicate that to preserve the positive
predictive value of the evaluated molecular tests, chromo-
somal assays should always be performed in conjunction
with plasmid PCR.
Because environmental and, to a lesser extent, clinical
samples may be heavily contaminated, a selective medium
for B. anthracis would be useful. PLET is used in environ-
mental investigations of agricultural anthrax outbreaks (3),
because it inhibits other bacilli and gram-negative rods
(10). In our study, the specificity of PLET was low, but
PLET is still valuable, because by inhibiting two thirds of
contaminating bacilli as well as other bacteria, background
will decrease and isolating colonies will be easier and
faster. However, the characteristic colony morphology of
the two B. anthracis strains on blood agar was not repro-
duced on PLET. Examination of a large number of B.
anthracis strains is required to confirm these observations. 
A positive correlation was detected between the ability
to grow on PLET and Ba813 PCR-positivity. Of note,
non–B. anthracis strains previously reported to be Ba813
PCR–positive were isolated by using PLET (20). Ba813-
positive bacilli may be very closely related to B. anthracis
and demonstrate, therefore, phenotypic similarities like the
ability to grow on PLET.
In conclusion, horse blood agar plates provide better
recognition of β-hemolysis, and testing after a 2-h incuba-
tion in TSB improves motility detection. The application
of these tests along with PLET agar will have a substantial
impact on public health laboratories that process large
numbers of specimens. Workload will decrease, and the
presence of B. anthracis will be ruled out faster, leading to
earlier termination of chemoprophylaxis and diminished
anxiety of exposed persons. Standardization and validation
of molecular assays as direct detection tests will further
decrease turnaround time; however, these methods only
complement conventional testing. Selective or differential
media and further refinement of conventional techniques
will still be needed.
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